KR20240082392A - Ige-매개된 질환의 치료 - Google Patents

Ige-매개된 질환의 치료 Download PDF

Info

Publication number
KR20240082392A
KR20240082392A KR1020247014489A KR20247014489A KR20240082392A KR 20240082392 A KR20240082392 A KR 20240082392A KR 1020247014489 A KR1020247014489 A KR 1020247014489A KR 20247014489 A KR20247014489 A KR 20247014489A KR 20240082392 A KR20240082392 A KR 20240082392A
Authority
KR
South Korea
Prior art keywords
ige
antibody
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247014489A
Other languages
English (en)
Korean (ko)
Inventor
비-셍 쿠오
차오-헝 리
얀-펑 리
수진 린
창이 왕
Original Assignee
유나이티드 바이오파마, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유나이티드 바이오파마, 인크. filed Critical 유나이티드 바이오파마, 인크.
Publication of KR20240082392A publication Critical patent/KR20240082392A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020247014489A 2021-10-12 2022-10-12 Ige-매개된 질환의 치료 Pending KR20240082392A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163254729P 2021-10-12 2021-10-12
US63/254,729 2021-10-12
PCT/CN2022/124777 WO2023061390A1 (en) 2021-10-12 2022-10-12 Treatment of ige-mediated diseases

Publications (1)

Publication Number Publication Date
KR20240082392A true KR20240082392A (ko) 2024-06-10

Family

ID=85981469

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247014489A Pending KR20240082392A (ko) 2021-10-12 2022-10-12 Ige-매개된 질환의 치료

Country Status (7)

Country Link
US (1) US20230122862A1 (https=)
EP (1) EP4416176A4 (https=)
JP (1) JP2024538791A (https=)
KR (1) KR20240082392A (https=)
CN (1) CN118119641A (https=)
TW (1) TW202332691A (https=)
WO (1) WO2023061390A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024050455A2 (en) * 2022-08-31 2024-03-07 Heitmeyer Jamie Nicole Anti-rhd antibodies for treating inflammatory dermal condition
WO2025015286A2 (en) * 2023-07-13 2025-01-16 Inhibrx Biosciences, Inc. Ige binding proteins and uses thereof
KR20260042217A (ko) 2023-07-13 2026-03-30 인히브릭스 바이오사이언스, 인크. IgE 결합 단백질 및 이의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012204078A1 (en) * 2007-02-15 2012-08-02 Astrazeneca Ab Binding members for IgE molecules
KR20140119777A (ko) * 2012-01-31 2014-10-10 제넨테크, 인크. 항-ig-e m1'' 항체 및 그의 사용 방법
DK3157951T3 (da) * 2014-06-17 2020-08-17 Academia Sinica Humaniserede anti-ige-antistoffer, der tværbinder cd23 på b-lymfocytter, men ikke sensibiliserer mastceller
JP6068582B2 (ja) * 2015-08-07 2017-01-25 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｂリンパ球上のヒトｍＩｇＥに結合可能な抗ＣεｍＸ抗体
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
WO2019085902A1 (en) * 2017-10-31 2019-05-09 Fountain Biopharma Inc. Treating ige-mediated allergic diseases

Also Published As

Publication number Publication date
JP2024538791A (ja) 2024-10-23
WO2023061390A1 (en) 2023-04-20
EP4416176A1 (en) 2024-08-21
TW202332691A (zh) 2023-08-16
EP4416176A4 (en) 2025-12-31
CN118119641A (zh) 2024-05-31
US20230122862A1 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
KR101637502B1 (ko) 치료용 개 면역글로불린 및 이를 이용하는 방법
EP3489258A1 (en) Il-6 antagonists and uses thereof
EP3215530B9 (en) Improved il-6 antibodies
KR20240082392A (ko) Ige-매개된 질환의 치료
AU2020350715A1 (en) GIPR antibody and fusion protein between same and GLP-1, and pharmaceutical composition and application thereof
CN117500835A (zh) 抗psma抗体及car-t结构
IL300660A (en) Antibodies against PAR-2 and methods of using them
US20230399390A1 (en) Novel anti-nogo-a antibodies
JP7725069B2 (ja) 抗ｔｆｐｉモノクローナル抗体
KR20250050855A (ko) Igf1r 항체
KR101804988B1 (ko) 신규 항-tfpi 항체 및 이를 포함하는 조성물
EP3808847A1 (en) Apj antibody, fusion protein thereof with elabela, and pharmaceutical compositions and use thereof
US20240141026A1 (en) Use of a periostin antibody for treating inflammation, fibrosis and lung diseases
RU2800370C2 (ru) Антитело к gipr и его слитый с glp-1 белок, а также фармацевтическая композиция на его основе и его применение
JP2025524927A (ja) カンナビノイド受容体１型結合タンパク質及びその使用
EP4729543A1 (en) Anti-il-4 receptor antibodies for veterinary use
TW202313693A (zh) 一種cdc平臺抗體
HK40027816A (en) Improved il-6 antibodies
HK40111253A (zh) 抗pacap抗体的组合物和方法
HK40102410A (en) Improved il-6 antibodies
TW202613177A (zh) Gipr抗體及其與glp-1的融合蛋白質，以及其藥物組合物和應用
HK1244008B (en) Improved il-6 antibodies

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240430

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application